PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30933843-6 2019 On the other hand, ambroxol treatment significantly reduced imiquimod-induced levels of inflammatory cytokines such as IL-1beta, IL-6, IL-17, IL-22, IL-23, TGF-beta, and TNF-alpha. Ambroxol 19-27 tumor necrosis factor Mus musculus 170-179 14504727-8 2004 Compared to the control group, TNF-alpha, IL-6 and TGF-beta1 levels in the BAL in both ambroxol- and dexamethasone-treated groups were significantly reduced at 24 and 48 h. The protein in BAL, an index of vascular permeability, was also significantly decreased in the ambroxol- and dexamethasone-treated groups (p<0.05). Ambroxol 87-95 tumor necrosis factor Mus musculus 31-40 26881857-7 2016 Four days of daily inhalation of ambroxol at 3.75 or 7.5mg/ml for 20 min suppressed the accumulation of neutrophils and macrophages in the bronchoalveolar lavage fluid (BALF) and lung tissues, and inhibited increases in the mRNA and protein levels of tumor necrosis factor (TNF)-alpha, CCL-2 and KC, but not interleukin (IL)-1beta in the CS-exposed mice. Ambroxol 33-41 tumor necrosis factor Mus musculus 251-284 30895504-11 2019 Pretreatment with AMB prevented the elevation of malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-alpha) level, reduction of total glutathione (GSH) that induced by CYP. Ambroxol 18-21 tumor necrosis factor Mus musculus 75-102 30895504-11 2019 Pretreatment with AMB prevented the elevation of malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-alpha) level, reduction of total glutathione (GSH) that induced by CYP. Ambroxol 18-21 tumor necrosis factor Mus musculus 104-113 26881857-11 2016 Using cultured lung epithelial cells, we demonstrated that pretreatment with ambroxol at 2 or 20 muM inhibited the CSE-induced up-regulation of MUC5AC, TNF-alpha, IL-1beta mRNA levels, which was through inhibiting Erk signaling pathway. Ambroxol 77-85 tumor necrosis factor Mus musculus 152-161